Reference Pricing
-
AMP is WAC — 10/03/25
Read more: AMP is WAC — 10/03/25Round ’em up. The Presidential priorities that have everything and nothing to do with each other. This week has been a healthcare whirlwind. Here’s what I think you need to know * Most favored nation policy is still kicking around and the company announcements are interesting, but I want to poke around under the hood…
-
Affordable Care Act, Caught my eye, Employers, Healthcare Costs, Medicaid, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 9/19/25
Read more: AMP is WAC — 9/19/25Work travel is usually a nice change of pace. And then I found myself on a Wednesday afternoon on the NJ Turnpike in torrential rain with other cars facing the wrong direction. Super fun! Two good things – 1) the pharma team I gave the talk to was awesome and 2) made it home safe…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Reference Pricing, Supply Chain, Utilization ManagementAMP is WAC — 9/12/25
Read more: AMP is WAC — 9/12/25On one hand, a busy week in the world of health policy. The quicksand of news in 2025 is real so I do my best to sidestep some news (MAHA report) to dive into the things that I think are important for my clients – including expected premium spikes, 340B rebate backlash and Medicare changes.…
-
340B, Caught my eye, Drug Prices, Generics, Medicare Part D, Medicare Transaction Facilitator, Orphan Drugs, Reference Pricing, VaccinesAMP is WAC — 09/04/25
Read more: AMP is WAC — 09/04/25A Monday off is always a double win, longer weekend and shorter week. Caught My Eye Made me Laugh. 340B can be funny. Go PhRMA. Zebras, Not Unicorns. The Food and Drug Administration announced a new rare disease approval framework. While it acknowledges the challenge of rare disease, it is unclear if the new framework…
-
Inflation Reduction Act, Medicare Advantage, Medicare Part D, Reference Pricing, State-based Reform, Supply Chain, VaccinesAMP is WAC — 8/15/25
Read more: AMP is WAC — 8/15/25Caught my Eye Surely a Coincidence. President Trump called for direct to consumer purchasing at Most Favored Nation Pricing and BlinkRx said that they could offer this service. Donald Trump Jr. is on their board. Lobby Me This. Stat News had an article about a new coalition, IRA Watch, that is formed to discuss…
-
340B, Alzheimer’s, Caught my eye, Drug Prices, Medicare Advantage, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference PricingAMP is WAC — 08/01/25
Read more: AMP is WAC — 08/01/25Rumor has it that the weather will be cooler in the DC-area this weekend and I am giddy. Outside time sounds great – a hike, a cocktail on the patio, maybe getting the friend group together to start planning the next ski trip… hope you get a chance to dream big too. Caught my…
-
AMP is WAC — 6/13/25
Read more: AMP is WAC — 6/13/25Caught my Eye Make Believe. This week we were wondering if the Administration would put out information on what the Most Favored Nation (MFN) would be for drugs; that is what is the best price for each drug in a set of country’s that have a GDP at least 60% of ours. But there have…
-
340B, Caught my eye, COVID, Drug Prices, Medicaid, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, VaccinesAMP is WAC — 05/30/25
Read more: AMP is WAC — 05/30/25I do love a Monday off. It somehow feels like an a double-treat – you get the Monday off and the week flies by. Yes we had to cram more meetings and work into the shorter week but totally worth it. Caught my Eye Processed Over. This week the Secretary of Health and Human Services,…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Drug shortages, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Preventative, Reference Pricing
Caught my eye — 5/16/25
Read more: Caught my eye — 5/16/25This week I’ve repeatedly spoken to groups about the President’s Executive Order (EO) on Most Favored Nation (MFN) pricing and I feel a little vulnerable. I am often “authentic” in my explanations. I recognize that to many people I seem biased on a lot of issues but, in my defense, I find most politics maddening…
-
Initial Take on MFN Executive Order, Part II
Read more: Initial Take on MFN Executive Order, Part IIInitial take at 3:30 today … which could change as I learn more… The foundational premise of the President’s new Executive Order (EO) is that the United States should pay less for drug and other countries should pay more; there should be an equalization. The Administration will take steps to work with foreign countries and…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)